Diagnostic and Monitoring Tests for Monoclonal Gammopathy of Undetermined Significance (MGUS)
Initial Diagnostic Workup
- The International Myeloma Working Group recommends a risk-stratified approach based on initial laboratory findings, with bone marrow examination and imaging studies reserved for patients with higher risk features or abnormal laboratory results, according to the International Myeloma Society 1, 2
- Complete blood count, serum calcium, and creatinine values should be performed to rule out end-organ damage, as suggested by the Leukemia society 1
- Qualitative test for urine protein should be done; if positive, perform urine protein electrophoresis and immunofixation, as recommended by the Leukemia society 1
- Serum protein electrophoresis (SPEP) should be performed to detect and quantify M-protein, according to the National Comprehensive Cancer Network 3, 4
- Serum immunofixation electrophoresis (SIFE) should be done to characterize the heavy and light chains of M-protein, as recommended by the National Comprehensive Cancer Network 3, 4
- Quantitative immunoglobulin levels (IgG, IgA, and IgM) should be measured, according to the National Comprehensive Cancer Network 3, 4
- Serum free light chain (FLC) assay with kappa/lambda ratio assessment should be performed, as recommended by the National Comprehensive Cancer Network and the Haematologica society 3, 2
Risk Stratification
- Patients with serum M-protein <15 g/L, IgG type, and normal FLC ratio are considered low-risk, according to the Haematologica society 2, 1
- Patients with serum M-protein >15 g/L, and/or IgA or IgM protein type, and/or abnormal FLC ratio are considered intermediate/high-risk, as recommended by the Haematologica society and the Leukemia society 2, 1
Additional Testing Based on Risk Category
- For low-risk MGUS, baseline bone marrow examination or skeletal radiography is not routinely indicated, according to the Leukemia society and the Haematologica society 1, 2
- For intermediate/high-risk MGUS, bone marrow aspirate and biopsy should be performed at baseline to rule out underlying plasma cell malignancy, as recommended by the Leukemia society 1, 5
- Both conventional cytogenetics and fluorescence in situ hybridization (FISH) should be performed on bone marrow examination, according to the Leukemia society 1, 5
- If available, plasma cell labeling index and search for circulating plasma cells using flow cytometry are useful, as recommended by the Leukemia society 1
- For IgM MGUS, a computed tomography scan of the abdomen should be done to check for asymptomatic retroperitoneal lymph nodes, according to the Leukemia society and the Haematologica society 1, 5
Monitoring Recommendations
- For low-risk MGUS, repeat SPEP in 6 months after diagnosis, and if stable, follow-up every 2-3 years or when symptoms suggestive of plasma cell malignancy arise, as recommended by the Leukemia society and the Haematologica society 1, 5
- For intermediate/high-risk MGUS, follow-up with SPEP and complete blood count in 6 months, and then annually for life, according to the Leukemia society and the Haematologica society 1, 5
Important Considerations and Pitfalls
- MGUS must be distinguished from smoldering multiple myeloma (SMM), which has a higher risk of progression, according to the Leukemia society and the Haematologica society 1, 5
- The risk of progression to malignancy does not diminish over time, necessitating lifelong follow-up, as recommended by the Haematologica society and the Leukemia society 2, 6
- Patients should be instructed to contact their physician if there is any change in their clinical condition, according to the Leukemia society and the Haematologica society 1, 5
- Bone marrow examination is always required if a patient with presumed MGUS has unexplained anemia, renal insufficiency, hypercalcemia, bone lesions, or suspicion of AL amyloidosis, as recommended by the Leukemia society and the Haematologica society 1, 5
- Treatment is not indicated for MGUS unless it is part of a clinical trial, according to the Leukemia society and the Haematologica society 1, 5